Referanslar

1. Nair PA, Atwater. Dermatitis, Contact [Uptodated 2017 oct 4]. ın: StatPearls [ınternet]. Treasure ısland (FL): Stat-Pearls Publishing; 2017 JunAvailable from: [Link]
2. Martin SF. Allergic contact dermatitis: xenoinflammation of the skin. Curr opin ımmunol. 2012;24(6):720-9. [Crossref]  [PubMed]
3. Alfonso JH, Bauer A, Bensefa-Colas L, Boman A, Bubas M, Constandt L,et al. Minimum stan-dards on prevention, diagnosis and treatment of occupational and work-related skin diseases in Europe-position paper of the CoST Action StanDerm (TD 1206). J Eur Acad Dermatol venereol. 2017;31(4):31-43. [Crossref]  [PubMed]
4. Martin SF, Esser PR, Schmucker S, Dietz L, Naisbitt DJ, Park BK, et al. T-cell recognition of chemicals, protein allergen sand drugs: toward-s the development of in vitro assays. Cell Mol-Life Sci. 2010;67(24):4171-84. [Crossref]  [PubMed]  [PMC]
5. Nosbaum A, vocanson M, Rozieres A, Hen-nino A, Nicolas JF. Allergic and irritant contact-dermatitis. Eur J Dermatol. 2009;19(4):325- 32. [Crossref]  [PubMed]
6. Coenraads PJ, Gonçalo M. Skin diseases withhigh public health impact. Contact dermatitis. Eur J Dermatol. 2007;17(6):564-5.
7. Cashman MW, Reutemann PA, Ehrlich A. Contact dermatitis in the United States: epidemiology, economic impact and work place prevention. Dermatol Clin. 2012;30(1):87-98. [Crossref]  [PubMed]  [PMC]
8. Peiser M, Tralau T, Heidler J, Api AM, Arts JH, Basketter DA, et al. Allergic contact dermatitis: epidemiology, molecular mechanisms in vit-ro methods and regulatory aspects. Current knowledge assembled at an international work shopat BfR, Germany. Cell Mol Life Sci. 2012; 69(5):763- 81. [Crossref]  [PubMed]  [PMC]
9. Jacob SE, Elsaie ML, Castanedo-Tardan MP, Stechschulte S, Kaufman J. Aging and contactdermatitis: a review. Curr Aging Sci. 2009;2(2): 121-6. [Crossref]  [PubMed]
10. Prakash Av, Davis MD. Contact dermatitis in older adults: a review of the literature. Am J Clin-Dermatol. 2010;11(6):373-81. [Crossref]  [PubMed]
11. Slodownik D, Lee A, Nixon R. ırritan tcontact-dermatitis: a review. Australas J Dermatol 2008;49(1):1-9. [Crossref]  [PubMed]
12. Bonneville M, Rozieres A, Chabeau G, SaintMezard P, Nicolas JF. Physiopathologie de la dermatite irritante de contact. ın: Progre's en Dermato-Allergologie. Montrouge, France:J ohn Libbey Eurotext; 2004, p. 177-88.
13. Kaplan DH, ıgyarto Bz, Gaspari AA. Early immune events in the induction of allergic contactdermatitis. Nat Rev ımmunol 2012;12(2): 114-24. [Crossref]  [PubMed]  [PMC]
14. Streit M, Braathen LR. Contact dermatitis: clinic sandpathology. Actaodontol Scand. 2001;59(5):309-14. [Crossref]  [PubMed]
15. Belsito Dv. The diagnostice valuation, treatment, and prevention of allergic contact dermatitis in the new millennium. J Allergy Clin ımmunol. 2000;105(3):409-20. [Crossref]  [PubMed]
16. Adışen E, Önder M. Akut allerjik kontakt dermatit ve foto kontakt dermatit. T Klin J Surg Med Sci. 2006;2(3):37-44.
17. Saint-Mezard P, Rozieres A, Krasteva M, Berard F, Dubois B, KaiserlianD, et al. Allergic contact-dermatitis. Eur J Dermatol. 2004;14 (5):284-95. [Crossref]  [PubMed]
18. Fyhrquist-vanni N, Alenius H, Lauerma A. Contact dermatitis. Dermatol Clin. 2007;25(4):613-23. [Crossref]  [PubMed]
19. Furio L, Guezennec A, Ducarre B, Guesnet J, Peguet-Navarro J. Differential effects of allergen-s and irritants on early differentiating monocyte-derived dendritic cells. Eur J Dermatol. 2008;18(2):141-7.
20. Griffiths CE, Dearman RJ, Cumberbatch M, Kimber ı. Cytokines and Langerhans cel lmobili-sation in Mouse and man. Cytokine. 2005; 32(2):67-70. [Crossref]  [PubMed]
21. de Jongh CM, Lutter R, verberk MM, Kezic S. Differential cytokine expression in skin after sin-gle and repeated irritation by sodium lauryl sulphate. Exp Dermatol. 2007;16(12):1032-40. [Crossref]  [PubMed]
22. Honda T, Egawa G, Grabbe S, Kabashima K. Update of immune events in the murine contact hypersensitivity model: toward the understanding of allergic contact dermatitis. J ınvest Dermatol. 2013;133(2):303-15. [Crossref]  [PubMed]
23. Kimber ı, Basketter DA, Gerberick GF, Dearman RJ. Allergic contact dermatitis. ınt ımmuno pharmacol. 2002;2(2-3):201-11. [Crossref]  [PubMed]
24. Vocanson M, Hennino A, Rozières A, Poyet G, Nicolas JF. Effector and regulatory mechanisms in allergic contact dermatitis. Allergy. 2009;64(12):1 699-714. [Crossref]  [PubMed]
25. Vocanson M, Hennino A, Chavagnac C, SaintMezard P, DuboisB, Kaiserlian D, et al. Contri-bution of CD4 + and CD8 + T cells in contact hypersensitivity and allergic contact dermatitis. Expert Rev Clin ımmunol. 2005;1(1):75-86. [Crossref]  [PubMed]
26. Cavani A. T regulatory cells in contact hypersensitivity. Curropin Allergy Clin ımmunol. 2008:8(4) 294-8. [Crossref]  [PubMed]
27. Fonacier L, Bernstein Dı, Pacheco K, Holness DL, Blessing-Moore J,Khan D, et al. Contact-Dermatitis: A Practice Parametere Update 2015. J Allergy Clın ımmunol Pract. 2015;3(3): S1-39. [Crossref]  [PubMed]
28. Gru AA, Salavaggione AL. Common spongiotic dermatoses. Semin Diagn Pathol. 2017;34(3):226- 36. [Crossref]  [PubMed]
29. Przybilla B, Rueff F. Contact dermatitis. ın: Burgdorf WHC, Plewig G, Wolf HH, Landthaler M. Braun-Falco's Dermatology. 3rd ed. Berlin: Springer-verlag; 2009. p.377-401. [Crossref]
30. Smedley J; oHCEU Dermatitis Group; BoHRF Dermatitis Group. Concise guidance: diagnosis, management and prevention of occupational contact dermatitis. Clin Med (Lond). 2010;10(5):487-90. [Crossref]  [PubMed]  [PMC]
31. Warshaw E, Lee G, Storrs FJ. Hand dermatitis: a reviewof clinical features, therapeutic options, and long term outcomes. Am J Contact Dermati-tis. 2003;14(3):119-37. [Crossref]  [PubMed]
32. Saary J, Qureshi R, Palda v, DeKoven J, Pratt M, Skotnicki-Grant S, et al. A systematic review of contact dermatitis treatment and prevention. J Am Acad Dermatol. 2005;53(5): 845. [Crossref]  [PubMed]
33. Niedner R. Grundlagen einer rationalen Thera-pie mit externen Glukokortikosteroiden. Hautarzt. 1991;42(5):337-46.
34. Luger TA, Loske KD, Elsner P, Kapp A, Kerscher M, Korting HC, et al. Topische Dermatotherapie mit Glukokortikoiden-Therapeu- tischer ındex. JDDG. 2004;2:629-34. [Crossref]  [PubMed]
35. veien NK, olholm Larsen P, Thestrup-Pedersen K, SchouG. Long-term, intermittent treatment of chronic hand eczema with mometa- sone furoate. Br J Dermatol. 1999;140(5): 882-6. [Crossref]  [PubMed]
36. Luger TA, Gollnick H. Stellungnahme der Deutschen Dermatologischen Gesellschaft (DDG) zur Entscheidungder amerikanischen Arzneimittelbehörde über die verwendungvon Pimecrolimus-Creme und Tacrolimus-Salbezur Behandlung der atopischen Dermatitis (Neuro-dermitis).JDDG. 2005;3(6):415-6. [Crossref]  [PubMed]
37. Aschoff R, Schmitt J, Knuschke P, Koch E, Bräutigam M, Meurer M. Evaluation of the atrophogenic potential of hydrocortisone 1% cream and pimecrolimus 1% creamin unin-volved forehead skin of patients with atopic der-matitis using optical coherence tomography. Exp Dermatol. 2011;20(10):832-6. [Crossref]  [PubMed]
38. Sjövall P, Christensen oB. Treatment of chronic hand eczema with Uv-B Handylux in the clinic and at home. Contact Dermatitis. 1994;31(1):5-8. [Crossref]  [PubMed]
39. Stege H. Ultravioletttherapie des chronischen Handekzems. Hautarzt. 2008;59(9):696-702 [Crossref]  [PubMed]
40. Brasch J, Becker D,Aberer W, Bircher A, Kranke B, Jung K, et al. Guidline contact der-matitis. S1- Guidelines of the German Contact Allergy Group (DKG) of the German Dermatol-ogy Society (DDG), the ınformation Network of Dermatological Clinics (ıvDK), the German So-ciety for Allergology and Clinical ımmunology (DGAKı), the Working Group for occupational and Environmental Dermatology (ABD) of the DDG, the Medical Association of German Aller-gologists (AeDA), the Professional Association of German Dermatologists (BvDD) and the DDG.Allergo J ınt. 2014;23(4):126-38. [Crossref]  [PubMed]  [PMC]